- Home
- DTIL vs IPSC Comparison
DTIL vs IPSC Comparison
Compare DTIL & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- IPSC
- Stock Information
- Founded
- DTIL 2006
- IPSC 2019
- Country
- DTIL United States
- IPSC United States
- Employees
- DTIL N/A
- IPSC N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- DTIL Health Care
- IPSC Health Care
- Exchange
- DTIL Nasdaq
- IPSC Nasdaq
- Market Cap
- DTIL 51.6M
- IPSC 49.6M
- IPO Year
- DTIL 2019
- IPSC 2021
- Fundamental
- Price
- DTIL $4.79
- IPSC $0.58
- Analyst Decision
- DTIL Strong Buy
- IPSC Strong Buy
- Analyst Count
- DTIL 2
- IPSC 5
- Target Price
- DTIL $47.00
- IPSC $3.33
- AVG Volume (30 Days)
- DTIL 85.2K
- IPSC 886.3K
- Earning Date
- DTIL 07-31-2025
- IPSC 08-07-2025
- Dividend Yield
- DTIL N/A
- IPSC N/A
- EPS Growth
- DTIL N/A
- IPSC N/A
- EPS
- DTIL N/A
- IPSC N/A
- Revenue
- DTIL $51,141,000.00
- IPSC $114,898,000.00
- Revenue This Year
- DTIL N/A
- IPSC $1,064.82
- Revenue Next Year
- DTIL $30.20
- IPSC N/A
- P/E Ratio
- DTIL N/A
- IPSC N/A
- Revenue Growth
- DTIL N/A
- IPSC 8286.72
- 52 Week Low
- DTIL $3.61
- IPSC $0.34
- 52 Week High
- DTIL $11.09
- IPSC $3.29
- Technical
- Relative Strength Index (RSI)
- DTIL 44.86
- IPSC 52.16
- Support Level
- DTIL $4.20
- IPSC $0.58
- Resistance Level
- DTIL $5.29
- IPSC $0.66
- Average True Range (ATR)
- DTIL 0.36
- IPSC 0.04
- MACD
- DTIL -0.03
- IPSC -0.00
- Stochastic Oscillator
- DTIL 36.88
- IPSC 41.52
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.